Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 26;11(7):896.
doi: 10.3390/cancers11070896.

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12

Francesco Autore  1 , Paolo Strati  2 , Idanna Innocenti  3 , Francesco Corrente  4 , Livio Trentin  5 , Agostino Cortelezzi  6 , Carlo Visco  7 , Marta Coscia  8   9 , Antonio Cuneo  10 , Alessandro Gozzetti  11 , Francesca Romana Mauro  12 , Anna Maria Frustaci  13 , Massimo Gentile  14 , Fortunato Morabito  15 , Stefano Molica  16 , Paolo Falcucci  17 , Giovanni D'Arena  18 , Roberta Murru  19 , Donatella Vincelli  20 , Dimitar G Efremov  21 , Antonietta Ferretti  22 , Gian Matteo Rigolin  23 , Candida Vitale  24   25 , Maria Chiara Tisi  26 , Gianluigi Reda  27 , Andrea Visentin  28 , Simona Sica  29   30 , Robin Foà  31 , Alessandra Ferrajoli  32 , Luca Laurenti  33   34
Affiliations

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12

Francesco Autore et al. Cancers (Basel). .

Abstract

Chronic Lymphocytic Leukemia (CLL) patients with +12 have been reported to have specific clinical and biologic features. We performed an analysis of the association between demographic; clinical; laboratory; biologic features and outcome in CLL patients with +12 to identify parameters predictive of disease progression; time to treatment; and survival. The study included 487 treatment-naive CLL patients with +12 from 15 academic centers; diagnosed between January 2000 and July 2016; and 816 treatment-naïve patients with absence of Fluorescence In Situ Hybridization (FISH) abnormalities. A cohort of 250 patients with +12 CLL followed at a single US institution was used for external validation. In patients with +12; parameters associated with worse prognosis in the multivariate model were high Lactate DeHydrogenase (LDH) and β-2-microglobulin and unmutated immunoglobulin heavy-chain variable region gene (IGHV). CLL patients with +12 and high LDH levels showed a shorter Progression-Free-Survival (PFS) (30 months vs. 65 months; p < 0.001), Treatment-Free-Survival (TFS) (33 months vs. 69 months; p < 0.001), Overall Survival (OS) (131 months vs. 181 months; p < 0.001) and greater CLL-related mortality (29% vs. 11% at 10 years; p < 0.001) when compared with +12 CLL patients with normal LDH levels. The same differences were observed in the validation cohort. These data suggest that serum LDH levels can predict PFS; TFS; OS and CLL-specific survival in CLL patients with +12.

Keywords: CLL; LDH; prognosis; trisomy 12.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Progression-free-survival (PFS) in patients with +12 chronic lymphocytic leukemia (CLL) vs. fluorescence in situ hybridization (FISH) negative CLL; (B) treatment-free-survival (TFS) in patients with +12 CLL vs. FISH negative CLL; (C) overall survival (OS) in patients with +12 CLL vs. FISH negative CLL.
Figure 2
Figure 2
(A) Progression-free-survival (PFS) in patients with +12 stratified according to Lactate DeHydrogenase (LDH) levels; (B) Treatment-free-survival (TFS) in patients with +12 stratified according to LDH levels; (C) Overall survival (OS) in patients with +12 stratified according to LDH levels.
Figure 3
Figure 3
Chronic Lymphocytic Leukemia (CLL)-specific survival in patients with +12 stratified according to Lactate DeHydrogenase (LDH) levels.
Figure 4
Figure 4
(A) Overall survival (OS) and (B) Chronic Lymphocytic Leukemia (CLL)-specific survival in +12 CLL patients with normal Lactate DeHydrogenase (LDH) levels vs. Fluorescence In Situ Hybridization (FISH) negative CLL patients.
Figure 5
Figure 5
Outcomes in the validation cohort by Lactate DeHydrogenase (LDH) levels: (A) Progression-free-survival (PFS); (B) Treatment-free-survival (TFS); (C) Overall survival (OS); and (D) Chronic Lymphocytic Leukemia (CLL)-specific survival.
See this image and copyright information in PMC

References

    1. Eichhorst B., Dreyling M., Robak T., Montserrat E., Hallek M., ESMO Guidelines Working Group Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2011;22:50–54. doi: 10.1093/annonc/mdr377. - DOI - PubMed
    1. Zenz T., Fröhling S., Mertens D., Döhner H., Stilgenbauer S. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL) Best Pr. Res. Clin. Haematol. 2010;23:71–84. doi: 10.1016/j.beha.2009.12.003. - DOI - PubMed
    1. Furman R.R. Prognostic markers and stratification of chronic lymphocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Program. 2010;2010:77–81. doi: 10.1182/asheducation-2010.1.77. - DOI - PubMed
    1. Pospisilova S., Gonzalez D., Malcikova J., Trbusek M., Rossi D., Kater A.P., Hillmen P. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012;26:1458–1461. doi: 10.1038/leu.2012.25. - DOI - PubMed
    1. Haferlach C., Dicker F., Schnittger S., Kern W., Haferlach T. Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442–2451. doi: 10.1038/sj.leu.2404935. - DOI - PubMed